Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 1/2020

01.06.2020 | Diagnostik in der Rheumatologie | Leitlinien

Management der frühen rheumatoiden Arthritis

Interdisziplinäre Leitlinie

verfasst von: Prof. Dr. M. Schneider, G. Baseler, O. Funken, S. Heberger, U. Kiltz, P. Klose, K. Krüger, J. Langhorst, W. Mau, R. Oltman, B. Richter, S. Seitz, P. Sewerin, R. Tholen, C. Weseloh, Univ.-Prof. Dr. M. Witthöft, C. Specker

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 1/2020

Einloggen, um Zugang zu erhalten

Auszug

Entwicklungsstufe: S3 …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Zink A, Albrecht K (2016) Wie häufig sind muskuloskeletale Erkrankungen in Deutschland? Z Rheumatol 75:346–353 PubMedCrossRef Zink A, Albrecht K (2016) Wie häufig sind muskuloskeletale Erkrankungen in Deutschland? Z Rheumatol 75:346–353 PubMedCrossRef
2.
Zurück zum Zitat Hense S, Luque Ramos A, Callhoff J, Albrecht K, Zink A, Hoffmann F (2016) Prävalenz der rheumatoiden arthritis in deutschland auf basis von Kassendaten. Z Rheumatol 75:819–827 PubMedCrossRef Hense S, Luque Ramos A, Callhoff J, Albrecht K, Zink A, Hoffmann F (2016) Prävalenz der rheumatoiden arthritis in deutschland auf basis von Kassendaten. Z Rheumatol 75:819–827 PubMedCrossRef
3.
Zurück zum Zitat Carmona L, Cross M, Williams B, Lassere M, March L (2010) Rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 24:733–745 CrossRef Carmona L, Cross M, Williams B, Lassere M, March L (2010) Rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 24:733–745 CrossRef
5.
Zurück zum Zitat Crowson CS, Matteson EL, Davis JM, Gabriel SE (2013) Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res 65:71–77 CrossRef Crowson CS, Matteson EL, Davis JM, Gabriel SE (2013) Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res 65:71–77 CrossRef
6.
Zurück zum Zitat Hedström AK, Stawiarz L, Klareskog L, Alfredsson L (2018) Smoking and susceptibility to rheumatoid arthritis in a swedish population-based case–control study. Eur J Epidemiol 33:415–423 PubMedPubMedCentralCrossRef Hedström AK, Stawiarz L, Klareskog L, Alfredsson L (2018) Smoking and susceptibility to rheumatoid arthritis in a swedish population-based case–control study. Eur J Epidemiol 33:415–423 PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising?: Results from olmsted county, minnesota, 1955–2007. Arthritis Rheum 62:1576–1582 PubMedPubMedCentralCrossRef Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising?: Results from olmsted county, minnesota, 1955–2007. Arthritis Rheum 62:1576–1582 PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Pedersen JK, Svendsen AJ, Hørslev-Petersen K (2007) Incidence of rheumatoid arthritis in the southern part of denmark from 1995 to 2001. TORJ 1:18–23 PubMedCrossRefPubMedCentral Pedersen JK, Svendsen AJ, Hørslev-Petersen K (2007) Incidence of rheumatoid arthritis in the southern part of denmark from 1995 to 2001. TORJ 1:18–23 PubMedCrossRefPubMedCentral
9.
Zurück zum Zitat Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM et al (2017) 2016 update of the eular recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959 PubMedCrossRef Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM et al (2017) 2016 update of the eular recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959 PubMedCrossRef
10.
Zurück zum Zitat Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P et al (2000) How does functional disability in early rheumatoid arthritis (ra) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the early ra study (eras). Rheumatology 39:603–611 PubMedCrossRef Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P et al (2000) How does functional disability in early rheumatoid arthritis (ra) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the early ra study (eras). Rheumatology 39:603–611 PubMedCrossRef
11.
Zurück zum Zitat Verstappen SM (2013) Outcomes of early rheumatoid arthritis—the who icf framework. Baillieres Best Pract Res Clin Rheumatol 27:555–570 CrossRef Verstappen SM (2013) Outcomes of early rheumatoid arthritis—the who icf framework. Baillieres Best Pract Res Clin Rheumatol 27:555–570 CrossRef
12.
Zurück zum Zitat Nikiphorou E, Norton S, Carpenter L, Dixey J, Walsh AD, Kiely P et al (2017) Secular changes in clinical features at presentation of rheumatoid arthritis: Increase in comorbidity but improved inflammatory states. Arthritis Care Res 69:21–27 CrossRef Nikiphorou E, Norton S, Carpenter L, Dixey J, Walsh AD, Kiely P et al (2017) Secular changes in clinical features at presentation of rheumatoid arthritis: Increase in comorbidity but improved inflammatory states. Arthritis Care Res 69:21–27 CrossRef
13.
Zurück zum Zitat Listing J, Kekow J, Manger B, Burmester G‑R, Pattloch D, Zink A et al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, tnfα inhibitors and rituximab. Ann Rheum Dis 74:415–421 PubMedCrossRef Listing J, Kekow J, Manger B, Burmester G‑R, Pattloch D, Zink A et al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, tnfα inhibitors and rituximab. Ann Rheum Dis 74:415–421 PubMedCrossRef
14.
Zurück zum Zitat Meune C, Touzé E, Trinquart L, Allanore Y (2009) Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 48:1309–1313 PubMedCrossRef Meune C, Touzé E, Trinquart L, Allanore Y (2009) Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 48:1309–1313 PubMedCrossRef
15.
Zurück zum Zitat Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel PL, Laan RF (2010) Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res 62:362–370 CrossRef Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel PL, Laan RF (2010) Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res 62:362–370 CrossRef
16.
Zurück zum Zitat Lindqvist E, Saxne T, Geborek P, Eberhardt K (2002) Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 61:1055–1059 PubMedPubMedCentralCrossRef Lindqvist E, Saxne T, Geborek P, Eberhardt K (2002) Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 61:1055–1059 PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC (1994) The severity of rheumatoid arthritis: a 6‑year followup study of younger women with symptoms of recent onset. J Rheumatol 21:1620–1625 PubMed van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC (1994) The severity of rheumatoid arthritis: a 6‑year followup study of younger women with symptoms of recent onset. J Rheumatol 21:1620–1625 PubMed
18.
Zurück zum Zitat Wiles NJ, Lunt M, Barrett EM, Bukhari M, Silman AJ, Symmons DP et al (2001) Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 44:1033–1042 PubMedCrossRef Wiles NJ, Lunt M, Barrett EM, Bukhari M, Silman AJ, Symmons DP et al (2001) Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 44:1033–1042 PubMedCrossRef
19.
Zurück zum Zitat Bukhari Ma S, Wiles NJ, Lunt M, Harrison BJ, Scott DGI, Symmons DPM et al (2003) Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48:46–53 PubMedCrossRef Bukhari Ma S, Wiles NJ, Lunt M, Harrison BJ, Scott DGI, Symmons DPM et al (2003) Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48:46–53 PubMedCrossRef
20.
Zurück zum Zitat Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ et al (2005) Anti-sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 7:R592–R603 PubMedPubMedCentralCrossRef Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ et al (2005) Anti-sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 7:R592–R603 PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Gorman JD (2006) Smoking and rheumatoid arthritis: another reason to just say no. Arthritis Rheum 54:10–13 PubMedCrossRef Gorman JD (2006) Smoking and rheumatoid arthritis: another reason to just say no. Arthritis Rheum 54:10–13 PubMedCrossRef
22.
Zurück zum Zitat Nielen MMJ, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L et al (2005) Antibodies to citrullinated human fibrinogen (acf) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 64:1199–1204 PubMedPubMedCentralCrossRef Nielen MMJ, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L et al (2005) Antibodies to citrullinated human fibrinogen (acf) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 64:1199–1204 PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Nyhäll-Wåhlin BM, Jacobsson LTH, Petersson IF, Turesson C, group Bs (2006) Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 65:601–606 PubMedCrossRef Nyhäll-Wåhlin BM, Jacobsson LTH, Petersson IF, Turesson C, group Bs (2006) Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 65:601–606 PubMedCrossRef
24.
Zurück zum Zitat Nell VPK, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M et al (2005) Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731–1736 PubMedPubMedCentralCrossRef Nell VPK, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M et al (2005) Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731–1736 PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163 PubMedCrossRef Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163 PubMedCrossRef
26.
Zurück zum Zitat Scott IC, Tan R, Stahl D, Steer S, Lewis CM, Cope AP (2013) The protective effect of alcohol on developing rheumatoid arthritis: A systematic review and meta-analysis. Rheumatology 52:856–867 PubMedCrossRef Scott IC, Tan R, Stahl D, Steer S, Lewis CM, Cope AP (2013) The protective effect of alcohol on developing rheumatoid arthritis: A systematic review and meta-analysis. Rheumatology 52:856–867 PubMedCrossRef
27.
Zurück zum Zitat Symmons DPM (2002) Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 16:707–722 CrossRef Symmons DPM (2002) Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 16:707–722 CrossRef
28.
Zurück zum Zitat van der Helm-van Mil AHM, le Cessie S, van Dongen H, Breedveld FC, Toes REM, Huizinga TWJ (2007) A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 56:433–440 PubMedCrossRef van der Helm-van Mil AHM, le Cessie S, van Dongen H, Breedveld FC, Toes REM, Huizinga TWJ (2007) A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 56:433–440 PubMedCrossRef
29.
Zurück zum Zitat van der Helm-van Mil AHM, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR et al (2008) Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 58:2241–2247 PubMedCrossRef van der Helm-van Mil AHM, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR et al (2008) Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 58:2241–2247 PubMedCrossRef
30.
Zurück zum Zitat Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357–365 PubMedCrossRef Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357–365 PubMedCrossRef
31.
Zurück zum Zitat Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D et al (2004) Autoantibodies recognizing citrullinated rat filaggrin in an elisa using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 135:173–180 PubMedPubMedCentralCrossRef Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D et al (2004) Autoantibodies recognizing citrullinated rat filaggrin in an elisa using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 135:173–180 PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Wolfe F, Zwillich SH (1998) The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 41:1072–1082 PubMedCrossRef Wolfe F, Zwillich SH (1998) The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 41:1072–1082 PubMedCrossRef
33.
Zurück zum Zitat van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH (2015) Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the leiden early arthritis clinic and espoir cohorts. Ann Rheum Dis 74:806–812 PubMedCrossRef van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH (2015) Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the leiden early arthritis clinic and espoir cohorts. Ann Rheum Dis 74:806–812 PubMedCrossRef
34.
Zurück zum Zitat Emery P (1995) Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 34(Suppl 2):87–90 PubMedCrossRef Emery P (1995) Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 34(Suppl 2):87–90 PubMedCrossRef
35.
Zurück zum Zitat Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS (1998) Early arthritis therapy: rationale and current approach. J Rheumatol Suppl 53:13–19 PubMed Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS (1998) Early arthritis therapy: rationale and current approach. J Rheumatol Suppl 53:13–19 PubMed
36.
Zurück zum Zitat Boers M (2003) Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 48:1771–1774 PubMedCrossRef Boers M (2003) Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 48:1771–1774 PubMedCrossRef
37.
Zurück zum Zitat O’Dell JR (2002) Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 46:283–285 PubMedCrossRef O’Dell JR (2002) Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 46:283–285 PubMedCrossRef
38.
Zurück zum Zitat Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS (2002) Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61:290–297 PubMedPubMedCentralCrossRef Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS (2002) Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61:290–297 PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588 PubMedCrossRef Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588 PubMedCrossRef
40.
Zurück zum Zitat Radner H, Neogi T, Smolen JS, Aletaha D (2014) Performance of the 2010 acr/eular classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 73:114–123 PubMedCrossRef Radner H, Neogi T, Smolen JS, Aletaha D (2014) Performance of the 2010 acr/eular classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 73:114–123 PubMedCrossRef
41.
Zurück zum Zitat Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2002) Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: Results from a primary care-based inception cohort of patients. Rheumatology 41:246–252 PubMedCrossRef Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2002) Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: Results from a primary care-based inception cohort of patients. Rheumatology 41:246–252 PubMedCrossRef
42.
Zurück zum Zitat Knevel R, Lukas C, van der Heijde D, Rincheval N, Combe B, van der Helm-van Mil AH (2013) Defining erosive disease typical of ra in the light of the acr/eular 2010 criteria for rheumatoid arthritis; results of the data driven phase. Ann Rheum Dis 72:590–595 PubMedCrossRef Knevel R, Lukas C, van der Heijde D, Rincheval N, Combe B, van der Helm-van Mil AH (2013) Defining erosive disease typical of ra in the light of the acr/eular 2010 criteria for rheumatoid arthritis; results of the data driven phase. Ann Rheum Dis 72:590–595 PubMedCrossRef
43.
Zurück zum Zitat Sokka T, Pincus T (2009) Erythrocyte sedimentation rate, c‑reactive protein, or rheumatoid factor are normal at presentation in 35 %–45 % of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from finland and the united states. J Rheumatol 36:1387–1390 PubMedCrossRef Sokka T, Pincus T (2009) Erythrocyte sedimentation rate, c‑reactive protein, or rheumatoid factor are normal at presentation in 35 %–45 % of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from finland and the united states. J Rheumatol 36:1387–1390 PubMedCrossRef
44.
Zurück zum Zitat Saraux A, Berthelot JM, Chalès G, Le Henaff C, Mary JY, Thorel JB et al (2002) Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 47:155–165 PubMedCrossRef Saraux A, Berthelot JM, Chalès G, Le Henaff C, Mary JY, Thorel JB et al (2002) Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 47:155–165 PubMedCrossRef
45.
Zurück zum Zitat Ioan-Facsinay A, el-Bannoudi H, Scherer HU, van der Woude D, Ménard HA, Lora M et al (2011) Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 70:188–193 PubMedCrossRef Ioan-Facsinay A, el-Bannoudi H, Scherer HU, van der Woude D, Ménard HA, Lora M et al (2011) Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 70:188–193 PubMedCrossRef
46.
Zurück zum Zitat Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503–2511 PubMedCrossRef Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503–2511 PubMedCrossRef
47.
Zurück zum Zitat Damjanovska L, Thabet MM, Levarth EW, Stoeken-Rijsbergen G, van der Voort EI, Toes RE et al (2010) Diagnostic value of anti-mcv antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 69:730–732 PubMedCrossRef Damjanovska L, Thabet MM, Levarth EW, Stoeken-Rijsbergen G, van der Voort EI, Toes RE et al (2010) Diagnostic value of anti-mcv antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 69:730–732 PubMedCrossRef
48.
Zurück zum Zitat Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 35:1002–1008 PubMed Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 35:1002–1008 PubMed
49.
Zurück zum Zitat Lee YH, Bae SC, Song GG (2015) Diagnostic accuracy of anti-mcv and anti-ccp antibodies in rheumatoid arthritis: a meta-analysis. Z Rheumatol 74:911–918 PubMedCrossRef Lee YH, Bae SC, Song GG (2015) Diagnostic accuracy of anti-mcv and anti-ccp antibodies in rheumatoid arthritis: a meta-analysis. Z Rheumatol 74:911–918 PubMedCrossRef
50.
Zurück zum Zitat Luime JJ, Colin EM, Hazes JMW, Lubberts E (2010) Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 69:337–344 PubMedCrossRef Luime JJ, Colin EM, Hazes JMW, Lubberts E (2010) Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 69:337–344 PubMedCrossRef
51.
Zurück zum Zitat Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L et al (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36–45 PubMedCrossRef Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L et al (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36–45 PubMedCrossRef
52.
Zurück zum Zitat Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S et al (2010) Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: Results from a 10-year prospective study. Ann Rheum Dis 69:345–351 PubMedCrossRef Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S et al (2010) Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: Results from a 10-year prospective study. Ann Rheum Dis 69:345–351 PubMedCrossRef
53.
Zurück zum Zitat van der Linden MPM, van der Woude D, Ioan-Facsinay A, Levarht EWN, Stoeken-Rijsbergen G, Huizinga TWJ et al (2009) Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60:2232–2241 PubMedCrossRef van der Linden MPM, van der Woude D, Ioan-Facsinay A, Levarht EWN, Stoeken-Rijsbergen G, Huizinga TWJ et al (2009) Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60:2232–2241 PubMedCrossRef
54.
Zurück zum Zitat Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808 PubMedCrossRef Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808 PubMedCrossRef
55.
Zurück zum Zitat Whiting PF, Smidt N, Sterne JAC, Harbord R, Burton A, Burke M et al (2010) Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 152:456–464; W155–66 PubMedCrossRef Whiting PF, Smidt N, Sterne JAC, Harbord R, Burton A, Burke M et al (2010) Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 152:456–464; W155–66 PubMedCrossRef
56.
Zurück zum Zitat Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and igm rheumatoid factors. Rheumatology 41:809–814 PubMedCrossRef Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and igm rheumatoid factors. Rheumatology 41:809–814 PubMedCrossRef
57.
Zurück zum Zitat Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G et al (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by iga-rf at disease onset. Ann Rheum Dis 65:453–458 PubMedCrossRef Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G et al (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by iga-rf at disease onset. Ann Rheum Dis 65:453–458 PubMedCrossRef
58.
Zurück zum Zitat Hensvold AH, Frisell T, Magnusson PKE, Holmdahl R, Askling J, Catrina AI (2017) How well do acpa discriminate and predict ra in the general population: a study based on 12 590 population-representative swedish twins. Ann Rheum Dis 76:119–125 PubMedCrossRef Hensvold AH, Frisell T, Magnusson PKE, Holmdahl R, Askling J, Catrina AI (2017) How well do acpa discriminate and predict ra in the general population: a study based on 12 590 population-representative swedish twins. Ann Rheum Dis 76:119–125 PubMedCrossRef
60.
Zurück zum Zitat Lindqvist E, Eberhardt K, Bendtzen K, Heinegård D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201 PubMedCrossRef Lindqvist E, Eberhardt K, Bendtzen K, Heinegård D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201 PubMedCrossRef
61.
Zurück zum Zitat Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L et al (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-cp) during 5 year follow up in early rheumatoid arthritis: Anti-cp status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749 PubMedPubMedCentralCrossRef Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L et al (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-cp) during 5 year follow up in early rheumatoid arthritis: Anti-cp status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749 PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat van Boekel MAM, Vossenaar ER, van den Hoogen FHJ, van Venrooij WJ (2002) Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. Arthritis Res 4:87–93 PubMedCrossRef van Boekel MAM, Vossenaar ER, van den Hoogen FHJ, van Venrooij WJ (2002) Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. Arthritis Res 4:87–93 PubMedCrossRef
63.
Zurück zum Zitat van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 50:709–715 PubMedCrossRef van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 50:709–715 PubMedCrossRef
64.
Zurück zum Zitat Nielen MMJ, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MHMT et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 50:380–386 PubMedCrossRef Nielen MMJ, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MHMT et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 50:380–386 PubMedCrossRef
65.
Zurück zum Zitat Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and iga rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749 PubMedCrossRef Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and iga rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749 PubMedCrossRef
66.
Zurück zum Zitat Mjaavatten MD, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K et al (2009) Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: Results from the nor-veac cohort. Arthritis Res Ther 11:R146 PubMedPubMedCentralCrossRef Mjaavatten MD, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K et al (2009) Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: Results from the nor-veac cohort. Arthritis Res Ther 11:R146 PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P et al (2008) High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: Results from a 10-year longitudinal study. Ann Rheum Dis 67:212–217 PubMedCrossRef Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P et al (2008) High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: Results from a 10-year longitudinal study. Ann Rheum Dis 67:212–217 PubMedCrossRef
68.
Zurück zum Zitat Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-ccp antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the swedish tira project). Ann Rheum Dis 63:1085–1089 PubMedPubMedCentralCrossRef Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-ccp antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the swedish tira project). Ann Rheum Dis 63:1085–1089 PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat Sanmartí R, Gómez-Centeno A, Ercilla G, Larrosa M, Viñas O, Vazquez I et al (2007) Prognostic factors of radiographic progression in early rheumatoid arthritis: A two year prospective study after a structured therapeutic strategy using dmards and very low doses of glucocorticoids. Clin Rheumatol 26:1111–1118 PubMedCrossRef Sanmartí R, Gómez-Centeno A, Ercilla G, Larrosa M, Viñas O, Vazquez I et al (2007) Prognostic factors of radiographic progression in early rheumatoid arthritis: A two year prospective study after a structured therapeutic strategy using dmards and very low doses of glucocorticoids. Clin Rheumatol 26:1111–1118 PubMedCrossRef
70.
Zurück zum Zitat Machold KP, Stamm TA, Eberl GJM, Nell VKP, Dunky A, Uffmann M et al (2002) Very recent onset arthritis—clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 29:2278–2287 PubMed Machold KP, Stamm TA, Eberl GJM, Nell VKP, Dunky A, Uffmann M et al (2002) Very recent onset arthritis—clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 29:2278–2287 PubMed
71.
Zurück zum Zitat Hetland ML, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG et al (2009) Mri bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (cimestra). Ann Rheum Dis 68:384–390 PubMedCrossRef Hetland ML, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG et al (2009) Mri bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (cimestra). Ann Rheum Dis 68:384–390 PubMedCrossRef
72.
Zurück zum Zitat Joshua F, Lassere M, Bruyn GA, Szkudlarek M, Naredo E, Schmidt WA et al (2007) Summary findings of a systematic review of the ultrasound assessment of synovitis. J Rheumatol 34:839–847 PubMed Joshua F, Lassere M, Bruyn GA, Szkudlarek M, Naredo E, Schmidt WA et al (2007) Summary findings of a systematic review of the ultrasound assessment of synovitis. J Rheumatol 34:839–847 PubMed
73.
Zurück zum Zitat Østergaard M, Pedersen SJ, Døhn UM (2008) Imaging in rheumatoid arthritis—status and recent advances for magnetic resonance imaging, ultrasonography, computed tomography and conventional radiography. Best Pract Res Clin Rheumatol 22:1019–1044 PubMedCrossRef Østergaard M, Pedersen SJ, Døhn UM (2008) Imaging in rheumatoid arthritis—status and recent advances for magnetic resonance imaging, ultrasonography, computed tomography and conventional radiography. Best Pract Res Clin Rheumatol 22:1019–1044 PubMedCrossRef
74.
Zurück zum Zitat Joshua F, Edmonds J, Lassere M (2006) Power doppler ultrasound in musculoskeletal disease: a systematic review. Semin Arthritis Rheum 36:99–108 PubMedCrossRef Joshua F, Edmonds J, Lassere M (2006) Power doppler ultrasound in musculoskeletal disease: a systematic review. Semin Arthritis Rheum 36:99–108 PubMedCrossRef
75.
Zurück zum Zitat Strunk J, Backhaus M, Schmidt W, Kellner H (2010) Color doppler sonography for investigation of peripheral joints and ligaments. Z Rheumatol 69:164–170 PubMedCrossRef Strunk J, Backhaus M, Schmidt W, Kellner H (2010) Color doppler sonography for investigation of peripheral joints and ligaments. Z Rheumatol 69:164–170 PubMedCrossRef
77.
Zurück zum Zitat Østergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B et al (2003) Omeract rheumatoid arthritis magnetic resonance imaging studies. Core set of mri acquisitions, joint pathology definitions, and the omeract ra-mri scoring system. J Rheumatol 30:1385–1386 PubMed Østergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B et al (2003) Omeract rheumatoid arthritis magnetic resonance imaging studies. Core set of mri acquisitions, joint pathology definitions, and the omeract ra-mri scoring system. J Rheumatol 30:1385–1386 PubMed
79.
Zurück zum Zitat van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJJ, Brouwer E, Codreanu C, Combe B et al (2017) Eular definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis 76:491–496 PubMedCrossRef van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJJ, Brouwer E, Codreanu C, Combe B et al (2017) Eular definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis 76:491–496 PubMedCrossRef
80.
Zurück zum Zitat Härter M (2004) Shared decision making—from the point of view of patients, physicians and health politics is set in place. Z Arztl Fortbild Qualitatssich 98:89–92 PubMed Härter M (2004) Shared decision making—from the point of view of patients, physicians and health politics is set in place. Z Arztl Fortbild Qualitatssich 98:89–92 PubMed
81.
Zurück zum Zitat Bieber C, Gschwendtner K, Müller N, Eich W (2016) Partizipative entscheidungsfindung (pef)—patient und arzt als team. Psychother Psychosom Med Psychol 66:195–207 PubMedCrossRef Bieber C, Gschwendtner K, Müller N, Eich W (2016) Partizipative entscheidungsfindung (pef)—patient und arzt als team. Psychother Psychosom Med Psychol 66:195–207 PubMedCrossRef
82.
Zurück zum Zitat Loh A, Simon D, Kriston L, Härter M (2007) Patientenbeteiligung bei medizinischen entscheidungen. Dtsch Arztebl Int 104:1483 Loh A, Simon D, Kriston L, Härter M (2007) Patientenbeteiligung bei medizinischen entscheidungen. Dtsch Arztebl Int 104:1483
83.
Zurück zum Zitat Wiek DBP, Clausen J (2016) Patientenbeteiligung an forschungsprojekten: Die forschungspartner der deutschen rheuma-liga. Z Rheumatol 75:236 CrossRef Wiek DBP, Clausen J (2016) Patientenbeteiligung an forschungsprojekten: Die forschungspartner der deutschen rheuma-liga. Z Rheumatol 75:236 CrossRef
87.
Zurück zum Zitat Gronning K, Skomsvoll JF, Rannestad T, Steinsbekk A (2012) The effect of an educational programme consisting of group and individual arthritis education for patients with polyarthritis—a randomised controlled trial. Patient Educ Couns 88:113–120 PubMedCrossRef Gronning K, Skomsvoll JF, Rannestad T, Steinsbekk A (2012) The effect of an educational programme consisting of group and individual arthritis education for patients with polyarthritis—a randomised controlled trial. Patient Educ Couns 88:113–120 PubMedCrossRef
93.
Zurück zum Zitat Niedermann K, Buchi S, Ciurea A, Kubli R, Steurer-Stey C, Villiger PM et al (2012) Six and 12 months’ effects of individual joint protection education in people with rheumatoid arthritis: a randomized controlled trial. Scand J Occup Ther 19:360–369 PubMedCrossRef Niedermann K, Buchi S, Ciurea A, Kubli R, Steurer-Stey C, Villiger PM et al (2012) Six and 12 months’ effects of individual joint protection education in people with rheumatoid arthritis: a randomized controlled trial. Scand J Occup Ther 19:360–369 PubMedCrossRef
94.
Zurück zum Zitat Pot-Vaucel M, Aubert MP, Guillot P, Glemarec J, Berthelot JM, Le Goff B et al (2016) Randomised study versus control group of customised therapeutic education for patients in follow-up for rheumatoid arthritis. Joint Bone Spine 83:199–206 PubMedCrossRef Pot-Vaucel M, Aubert MP, Guillot P, Glemarec J, Berthelot JM, Le Goff B et al (2016) Randomised study versus control group of customised therapeutic education for patients in follow-up for rheumatoid arthritis. Joint Bone Spine 83:199–206 PubMedCrossRef
95.
Zurück zum Zitat Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA (2001) Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60:924–927 PubMedPubMedCentralCrossRef Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA (2001) Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60:924–927 PubMedPubMedCentralCrossRef
96.
Zurück zum Zitat Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G (2011) Very early rheumatoid arthritis is the major predictor of major outcomes: clinical acr remission and radiographic non-progression. Ann Rheum Dis 70:1292–1295 PubMedCrossRef Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G (2011) Very early rheumatoid arthritis is the major predictor of major outcomes: clinical acr remission and radiographic non-progression. Ann Rheum Dis 70:1292–1295 PubMedCrossRef
97.
Zurück zum Zitat Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U et al (1995) Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 22:2208–2213 PubMed Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U et al (1995) Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 22:2208–2213 PubMed
98.
Zurück zum Zitat Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R et al (2013) Very early rheumatoid arthritis as a predictor of remission: A multicentre real life prospective study. Ann Rheum Dis 72:858–862 PubMedCrossRef Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R et al (2013) Very early rheumatoid arthritis as a predictor of remission: A multicentre real life prospective study. Ann Rheum Dis 72:858–862 PubMedCrossRef
99.
Zurück zum Zitat Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M’Seffar A et al (2000) Consequences of delayed therapy with second-line agents in rheumatoid arthritis: A 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (hera) study. J Rheumatol 27:623–629 PubMed Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M’Seffar A et al (2000) Consequences of delayed therapy with second-line agents in rheumatoid arthritis: A 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (hera) study. J Rheumatol 27:623–629 PubMed
100.
Zurück zum Zitat Hua C, Daien CI, Combe B, Landewe R (2017) Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the eular recommendations for the management of early arthritis. RMD Open 3:e406 PubMedPubMedCentralCrossRef Hua C, Daien CI, Combe B, Landewe R (2017) Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the eular recommendations for the management of early arthritis. RMD Open 3:e406 PubMedPubMedCentralCrossRef
101.
Zurück zum Zitat van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Ewals JAPM, Han KH, Hazes JMW et al (2008) Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Care Res 61:4–12 CrossRef van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Ewals JAPM, Han KH, Hazes JMW et al (2008) Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Care Res 61:4–12 CrossRef
102.
Zurück zum Zitat Wiles NJ, Dunn G, Barrett EM, Harrison BJ, Silman AJ, Symmons DP (2000) One year followup variables predict disability 5 years after presentation with inflammatory polyarthritis with greater accuracy than at baseline. J Rheumatol 27:2360–2366 PubMed Wiles NJ, Dunn G, Barrett EM, Harrison BJ, Silman AJ, Symmons DP (2000) One year followup variables predict disability 5 years after presentation with inflammatory polyarthritis with greater accuracy than at baseline. J Rheumatol 27:2360–2366 PubMed
103.
Zurück zum Zitat Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazes JMW et al (2002) Early and aggressive treatment of rheumatoid arthritis patients affects the association of hla class ii antigens with progression of joint damage. Arthritis Rheum 46:899–905 PubMedCrossRef Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazes JMW et al (2002) Early and aggressive treatment of rheumatoid arthritis patients affects the association of hla class ii antigens with progression of joint damage. Arthritis Rheum 46:899–905 PubMedCrossRef
104.
Zurück zum Zitat Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde D (2011) Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the etude et suivi des polyarthrites indifferenciees recentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 63:1804–1811 PubMedCrossRef Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde D (2011) Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the etude et suivi des polyarthrites indifferenciees recentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 63:1804–1811 PubMedCrossRef
105.
Zurück zum Zitat Möttönen T, Hannonen P, Korpela M, Nissilä M, Kautiainen H, Ilonen J et al (2002) Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898 PubMedCrossRef Möttönen T, Hannonen P, Korpela M, Nissilä M, Kautiainen H, Ilonen J et al (2002) Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898 PubMedCrossRef
106.
Zurück zum Zitat Soderlin MK, Bergman S (2011) Absent “window of opportunity” in smokers with short disease duration. Data from barfot, a multicenter study of early rheumatoid arthritis. J Rheumatol 38:2160–2168 PubMedCrossRef Soderlin MK, Bergman S (2011) Absent “window of opportunity” in smokers with short disease duration. Data from barfot, a multicenter study of early rheumatoid arthritis. J Rheumatol 38:2160–2168 PubMedCrossRef
107.
Zurück zum Zitat Monti S, Montecucco C, Bugatti S, Caporali R (2015) Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open 1:e57 PubMedPubMedCentralCrossRef Monti S, Montecucco C, Bugatti S, Caporali R (2015) Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open 1:e57 PubMedPubMedCentralCrossRef
109.
Zurück zum Zitat van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes REM, van der Heijde D et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 60:2262–2271 PubMedCrossRef van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes REM, van der Heijde D et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 60:2262–2271 PubMedCrossRef
111.
Zurück zum Zitat van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HMJ et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424–1432 PubMedCrossRef van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HMJ et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424–1432 PubMedCrossRef
112.
Zurück zum Zitat Peltomaa R, Paimela L, Kautiainen H, Leirisalo-Repo M (2002) Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann Rheum Dis 61:889–894 PubMedPubMedCentralCrossRef Peltomaa R, Paimela L, Kautiainen H, Leirisalo-Repo M (2002) Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann Rheum Dis 61:889–894 PubMedPubMedCentralCrossRef
113.
Zurück zum Zitat van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM et al (2000) Aggressive treatment in early rheumatoid arthritis: A randomised controlled trial. On behalf of the rheumatic research foundation utrecht, the netherlands. Ann Rheum Dis 59:468–477 PubMedPubMedCentralCrossRef van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM et al (2000) Aggressive treatment in early rheumatoid arthritis: A randomised controlled trial. On behalf of the rheumatic research foundation utrecht, the netherlands. Ann Rheum Dis 59:468–477 PubMedPubMedCentralCrossRef
114.
Zurück zum Zitat Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15 PubMedCrossRef Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15 PubMedCrossRef
115.
Zurück zum Zitat Möttönen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M (1996) Outcome in patients with early rheumatoid arthritis treated according to the “sawtooth” strategy. Arthritis Rheum 39:996–1005 PubMedCrossRef Möttönen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M (1996) Outcome in patients with early rheumatoid arthritis treated according to the “sawtooth” strategy. Arthritis Rheum 39:996–1005 PubMedCrossRef
116.
Zurück zum Zitat Fries JF, Williams CA, Ramey D, Bloch DA (1993) The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 36:297–306 PubMedCrossRef Fries JF, Williams CA, Ramey D, Bloch DA (1993) The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 36:297–306 PubMedCrossRef
117.
Zurück zum Zitat Tijhuis GJ, Zwinderman AH, Hazes JMW, Van Den Hout WB, Breedveld FC, Vliet Vlieland TPM (2002) A randomized comparison of care provided by a clinical nurse specialist, an inpatient team, and a day patient team in rheumatoid arthritis. Arthritis Rheum 47:525–531 PubMedCrossRef Tijhuis GJ, Zwinderman AH, Hazes JMW, Van Den Hout WB, Breedveld FC, Vliet Vlieland TPM (2002) A randomized comparison of care provided by a clinical nurse specialist, an inpatient team, and a day patient team in rheumatoid arthritis. Arthritis Rheum 47:525–531 PubMedCrossRef
118.
Zurück zum Zitat Vliet Vlieland TP, Zwinderman AH, Vandenbroucke JP, Breedveld FC, Hazes JM (1996) A randomized clinical trial of in-patient multidisciplinary treatment versus routine out-patient care in active rheumatoid arthritis. Br J Rheumatol 35:475–482 PubMedCrossRef Vliet Vlieland TP, Zwinderman AH, Vandenbroucke JP, Breedveld FC, Hazes JM (1996) A randomized clinical trial of in-patient multidisciplinary treatment versus routine out-patient care in active rheumatoid arthritis. Br J Rheumatol 35:475–482 PubMedCrossRef
119.
Zurück zum Zitat Vliet Vlieland TP, Breedveld FC, Hazes JM (1997) The two-year follow-up of a randomized comparison of in-patient multidisciplinary team care and routine out-patient care for active rheumatoid arthritis. Br J Rheumatol 36:82–85 PubMedCrossRef Vliet Vlieland TP, Breedveld FC, Hazes JM (1997) The two-year follow-up of a randomized comparison of in-patient multidisciplinary team care and routine out-patient care for active rheumatoid arthritis. Br J Rheumatol 36:82–85 PubMedCrossRef
120.
Zurück zum Zitat Helewa A, Bombardier C, Goldsmith CH, Menchions B, Smythe HA (1989) Cost-effectiveness of inpatient and intensive outpatient treatment of rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum 32:1505–1514 PubMedCrossRef Helewa A, Bombardier C, Goldsmith CH, Menchions B, Smythe HA (1989) Cost-effectiveness of inpatient and intensive outpatient treatment of rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum 32:1505–1514 PubMedCrossRef
121.
Zurück zum Zitat Lambert CM, Hurst NP, Forbes JF, Lochhead A, Macleod M, Nuki G (1998) Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. BMJ 316:965–969 PubMedPubMedCentralCrossRef Lambert CM, Hurst NP, Forbes JF, Lochhead A, Macleod M, Nuki G (1998) Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. BMJ 316:965–969 PubMedPubMedCentralCrossRef
122.
Zurück zum Zitat Ayhan F (2011) Long-term effects of comprehensive inpatient rehabilitation on function and disease activity in patients with chronic rheumatoid arthritis and ankylosing spondylitis. Turk J Rheumatol 26:135–144 CrossRef Ayhan F (2011) Long-term effects of comprehensive inpatient rehabilitation on function and disease activity in patients with chronic rheumatoid arthritis and ankylosing spondylitis. Turk J Rheumatol 26:135–144 CrossRef
123.
Zurück zum Zitat Bearne LM, Byrne A‑M, Segrave H, White CM (2016) Multidisciplinary team care for people with rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int 36:311–324 PubMedCrossRef Bearne LM, Byrne A‑M, Segrave H, White CM (2016) Multidisciplinary team care for people with rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int 36:311–324 PubMedCrossRef
124.
Zurück zum Zitat van den Hout WB, Tijhuis GJ, Hazes JMW, Breedveld FC, Vliet Vlieland TPM (2003) Cost effectiveness and cost utility analysis of multidisciplinary care in patients with rheumatoid arthritis: A randomised comparison of clinical nurse specialist care, inpatient team care, and day patient team care. Ann Rheum Dis 62:308–315 PubMedPubMedCentralCrossRef van den Hout WB, Tijhuis GJ, Hazes JMW, Breedveld FC, Vliet Vlieland TPM (2003) Cost effectiveness and cost utility analysis of multidisciplinary care in patients with rheumatoid arthritis: A randomised comparison of clinical nurse specialist care, inpatient team care, and day patient team care. Ann Rheum Dis 62:308–315 PubMedPubMedCentralCrossRef
125.
Zurück zum Zitat de Buck PDM, Schoones JW, Allaire SH, Vliet Vlieland TPM (2002) Vocational rehabilitation in patients with chronic rheumatic diseases: a systematic literature review. Semin Arthritis Rheum 32:196–203 PubMedCrossRef de Buck PDM, Schoones JW, Allaire SH, Vliet Vlieland TPM (2002) Vocational rehabilitation in patients with chronic rheumatic diseases: a systematic literature review. Semin Arthritis Rheum 32:196–203 PubMedCrossRef
126.
Zurück zum Zitat Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J et al (2011) American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413 PubMedCrossRef Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J et al (2011) American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413 PubMedCrossRef
127.
Zurück zum Zitat Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: A randomized trial. Ann Intern Med 146:406–415 PubMedCrossRef Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: A randomized trial. Ann Intern Med 146:406–415 PubMedCrossRef
128.
Zurück zum Zitat Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the ticora study): A single-blind randomised controlled trial. Lancet 364:263–269 PubMedCrossRef Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the ticora study): A single-blind randomised controlled trial. Lancet 364:263–269 PubMedCrossRef
130.
Zurück zum Zitat Kaneko Y, Kondo H, Takeuchi T (2013) American college of rheumatology/european league against rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints. J Rheumatol 40:1254–1258 PubMedCrossRef Kaneko Y, Kondo H, Takeuchi T (2013) American college of rheumatology/european league against rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints. J Rheumatol 40:1254–1258 PubMedCrossRef
131.
Zurück zum Zitat Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML et al (2012) Remission and radiographic outcome in rheumatoid arthritis: Application of the 2011 acr/eular remission criteria in an observational cohort. Ann Rheum Dis 71:681–686 PubMedCrossRef Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML et al (2012) Remission and radiographic outcome in rheumatoid arthritis: Application of the 2011 acr/eular remission criteria in an observational cohort. Ann Rheum Dis 71:681–686 PubMedCrossRef
132.
Zurück zum Zitat Balsa A, de Miguel E, Castillo C, Peiteado D, Martin-Mola E (2010) Superiority of sdai over das-28 in assessment of remission in rheumatoid arthritis patients using power doppler ultrasonography as a gold standard. Rheumatology 49:683–690 PubMedCrossRef Balsa A, de Miguel E, Castillo C, Peiteado D, Martin-Mola E (2010) Superiority of sdai over das-28 in assessment of remission in rheumatoid arthritis patients using power doppler ultrasonography as a gold standard. Rheumatology 49:683–690 PubMedCrossRef
133.
Zurück zum Zitat Sakellariou G, Scire CA, Verstappen SM, Montecucco C, Caporali R (2013) In patients with early rheumatoid arthritis, the new acr/eular definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis 72:245–249 PubMedCrossRef Sakellariou G, Scire CA, Verstappen SM, Montecucco C, Caporali R (2013) In patients with early rheumatoid arthritis, the new acr/eular definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis 72:245–249 PubMedCrossRef
134.
Zurück zum Zitat Kommission bildgebende verfahren der dgrh (2007) Bildgebende verfahren in der rheumatologie. Steinkopff, Darmstadt Kommission bildgebende verfahren der dgrh (2007) Bildgebende verfahren in der rheumatologie. Steinkopff, Darmstadt
135.
Zurück zum Zitat Bijlsma JW, Welsing PM, Woodworth TG, Middelink LM, Petho-Schramm A, Bernasconi C et al (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (u-act-early): A multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388:343–355 PubMedCrossRef Bijlsma JW, Welsing PM, Woodworth TG, Middelink LM, Petho-Schramm A, Bernasconi C et al (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (u-act-early): A multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388:343–355 PubMedCrossRef
138.
Zurück zum Zitat Horslev-Petersen K, Hetland ML, Junker P, Podenphant J, Ellingsen T, Ahlquist P et al (2014) Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The opera study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 73:654–661 PubMedCrossRef Horslev-Petersen K, Hetland ML, Junker P, Podenphant J, Ellingsen T, Ahlquist P et al (2014) Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The opera study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 73:654–661 PubMedCrossRef
139.
Zurück zum Zitat Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P et al (2014) Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: The randomised controlled optima trial. Lancet 383:321–332 PubMedCrossRef Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P et al (2014) Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: The randomised controlled optima trial. Lancet 383:321–332 PubMedCrossRef
141.
Zurück zum Zitat Gøtzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL et al (1996) Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 25:194–199 PubMedCrossRef Gøtzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL et al (1996) Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 25:194–199 PubMedCrossRef
142.
Zurück zum Zitat ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM et al (1996) Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347:347–352 PubMedCrossRef ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM et al (1996) Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347:347–352 PubMedCrossRef
143.
Zurück zum Zitat Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33:1449–1461 PubMedCrossRef Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33:1449–1461 PubMedCrossRef
144.
Zurück zum Zitat Sokka T, Hannonen P (1999) Utility of disease modifying antirheumatic drugs in “sawtooth” strategy. A prospective study of early rheumatoid arthritis patients up to 15 years. Ann Rheum Dis 58:618–622 PubMedPubMedCentralCrossRef Sokka T, Hannonen P (1999) Utility of disease modifying antirheumatic drugs in “sawtooth” strategy. A prospective study of early rheumatoid arthritis patients up to 15 years. Ann Rheum Dis 58:618–622 PubMedPubMedCentralCrossRef
145.
Zurück zum Zitat Capell HA, Murphy EA, Hunter JA (1991) Rheumatoid arthritis: workload and outcome over 10 years. Q J Med 79:461–476 PubMed Capell HA, Murphy EA, Hunter JA (1991) Rheumatoid arthritis: workload and outcome over 10 years. Q J Med 79:461–476 PubMed
147.
Zurück zum Zitat Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A (2013) A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in ra and their impact on outcome. Rheumatology 52:99–110 PubMedCrossRef Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A (2013) A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in ra and their impact on outcome. Rheumatology 52:99–110 PubMedCrossRef
148.
Zurück zum Zitat Kleinert S, Krueger K (2011) Kardiovaskuläre komorbidität und ihre risikofaktoren bei rheumatoider arthritis. Z Rheumatol 70:464–472 PubMedCrossRef Kleinert S, Krueger K (2011) Kardiovaskuläre komorbidität und ihre risikofaktoren bei rheumatoider arthritis. Z Rheumatol 70:464–472 PubMedCrossRef
149.
Zurück zum Zitat Cavagna L, Monti S, Grosso V, Boffini N, Scorletti E, Crepaldi G et al (2013) The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int 2013:759760 PubMedPubMedCentralCrossRef Cavagna L, Monti S, Grosso V, Boffini N, Scorletti E, Crepaldi G et al (2013) The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int 2013:759760 PubMedPubMedCentralCrossRef
150.
Zurück zum Zitat Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y et al (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Ann Rheum Dis 74:326–332 PubMedCrossRef Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y et al (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Ann Rheum Dis 74:326–332 PubMedCrossRef
151.
Zurück zum Zitat Choy EH, Scott DL, Kingsley GH, Williams P, Wojtulewski J, Papasavvas G et al (2002) Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: A randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol 20:351–358 PubMed Choy EH, Scott DL, Kingsley GH, Williams P, Wojtulewski J, Papasavvas G et al (2002) Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: A randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol 20:351–358 PubMed
152.
Zurück zum Zitat Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68:1870–1877 PubMedCrossRef Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68:1870–1877 PubMedCrossRef
153.
Zurück zum Zitat Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E et al (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled avert study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19–26 PubMedCrossRef Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E et al (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled avert study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19–26 PubMedCrossRef
154.
Zurück zum Zitat Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al (2006) The premier study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37 PubMedCrossRef Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al (2006) The premier study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37 PubMedCrossRef
155.
Zurück zum Zitat Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan A‑M, Walker D et al (2008) Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59:1467–1474 PubMedCrossRef Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan A‑M, Walker D et al (2008) Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59:1467–1474 PubMedCrossRef
156.
Zurück zum Zitat Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T et al (2014) Adalimumab, a human anti-tnf monoclonal antibody, outcome study for the prevention of joint damage in japanese patients with early rheumatoid arthritis: The hopeful 1 study. Ann Rheum Dis 73:536–543 PubMedCrossRef Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T et al (2014) Adalimumab, a human anti-tnf monoclonal antibody, outcome study for the prevention of joint damage in japanese patients with early rheumatoid arthritis: The hopeful 1 study. Ann Rheum Dis 73:536–543 PubMedCrossRef
158.
Zurück zum Zitat Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X et al (2017) Certolizumab pegol in combination with dose-optimised methotrexate in dmard-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1‑year results from c‑early, a randomised, double-blind, placebo-controlled phase iii study. Ann Rheum Dis 76:96–104 PubMedCrossRef Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X et al (2017) Certolizumab pegol in combination with dose-optimised methotrexate in dmard-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1‑year results from c‑early, a randomised, double-blind, placebo-controlled phase iii study. Ann Rheum Dis 76:96–104 PubMedCrossRef
159.
Zurück zum Zitat Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586–1593 PubMedCrossRef Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586–1593 PubMedCrossRef
160.
Zurück zum Zitat Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (comet): A randomised, double-blind, parallel treatment trial. Lancet 372:375–382 PubMedCrossRef Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (comet): A randomised, double-blind, parallel treatment trial. Lancet 372:375–382 PubMedCrossRef
161.
Zurück zum Zitat Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P et al (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60:2272–2283 PubMedCrossRef Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P et al (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60:2272–2283 PubMedCrossRef
162.
Zurück zum Zitat St Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443 PubMedCrossRef St Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443 PubMedCrossRef
164.
Zurück zum Zitat Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A et al (2016) Tocilizumab in early progressive rheumatoid arthritis: function, a randomised controlled trial. Ann Rheum Dis 75:1081–1091 PubMedCrossRef Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A et al (2016) Tocilizumab in early progressive rheumatoid arthritis: function, a randomised controlled trial. Ann Rheum Dis 75:1081–1091 PubMedCrossRef
165.
Zurück zum Zitat Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS et al (2006) Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 54:1401–1409 PubMedCrossRef Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS et al (2006) Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 54:1401–1409 PubMedCrossRef
166.
Zurück zum Zitat Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS et al (2008) Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: Second-year clinical and radiographic results from the cimestra study. Ann Rheum Dis 67:815–822 PubMedCrossRef Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS et al (2008) Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: Second-year clinical and radiographic results from the cimestra study. Ann Rheum Dis 67:815–822 PubMedCrossRef
167.
Zurück zum Zitat van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB (1989) Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036–1038 PubMedCrossRef van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB (1989) Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036–1038 PubMedCrossRef
168.
Zurück zum Zitat Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. Fin-raco trial group. Lancet 353:1568–1573 PubMedCrossRef Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. Fin-raco trial group. Lancet 353:1568–1573 PubMedCrossRef
169.
Zurück zum Zitat Landewé RB, Goei Thè HS, van Rijthoven AW, Breedveld FC, Dijkmans BA (1994) A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 37:637–643 PubMedCrossRef Landewé RB, Goei Thè HS, van Rijthoven AW, Breedveld FC, Dijkmans BA (1994) A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 37:637–643 PubMedCrossRef
170.
Zurück zum Zitat Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D et al (2000) Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin a, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 43:1809–1819 PubMedCrossRef Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D et al (2000) Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin a, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 43:1809–1819 PubMedCrossRef
171.
Zurück zum Zitat Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB (1997) Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 36:1082–1088 PubMedCrossRef Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB (1997) Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 36:1082–1088 PubMedCrossRef
172.
Zurück zum Zitat Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M et al (1999) Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58:220–225 PubMedPubMedCentralCrossRef Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M et al (1999) Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58:220–225 PubMedPubMedCentralCrossRef
173.
Zurück zum Zitat Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318 PubMedCrossRef Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318 PubMedCrossRef
174.
Zurück zum Zitat van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E et al (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (swefot trial): 1‑year results of a randomised trial. Lancet 374:459–466 PubMedCrossRef van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E et al (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (swefot trial): 1‑year results of a randomised trial. Lancet 374:459–466 PubMedCrossRef
175.
Zurück zum Zitat Hannonen P, Möttönen T, Hakola M, Oka M (1993) Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 36:1501–1509 PubMedCrossRef Hannonen P, Möttönen T, Hakola M, Oka M (1993) Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 36:1501–1509 PubMedCrossRef
176.
Zurück zum Zitat Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506–517 PubMedPubMedCentralCrossRef Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506–517 PubMedPubMedCentralCrossRef
177.
Zurück zum Zitat Fleischmann RM, Huizinga TWJ, Kavanaugh AF, Wilkinson B, Kwok K, DeMasi R et al (2016) Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2:e262 PubMedPubMedCentralCrossRef Fleischmann RM, Huizinga TWJ, Kavanaugh AF, Wilkinson B, Kwok K, DeMasi R et al (2016) Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2:e262 PubMedPubMedCentralCrossRef
178.
Zurück zum Zitat Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377–2386 PubMedCrossRef Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377–2386 PubMedCrossRef
187.
Zurück zum Zitat Fries JF, Williams CA, Morfeld D, Singh G, Sibley J (1996) Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 39:616–622 PubMedCrossRef Fries JF, Williams CA, Morfeld D, Singh G, Sibley J (1996) Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 39:616–622 PubMedCrossRef
188.
Zurück zum Zitat Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 359:1173–1177 PubMedCrossRef Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 359:1173–1177 PubMedCrossRef
189.
Zurück zum Zitat Krause D, Schleusser B, Herborn G, Rau R (2000) Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43:14–21 PubMedCrossRef Krause D, Schleusser B, Herborn G, Rau R (2000) Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43:14–21 PubMedCrossRef
190.
Zurück zum Zitat Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E (2002) Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin a, sulphasalazine) or monotherapy for three years. Rheumatology 41:892–898 PubMedCrossRef Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E (2002) Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin a, sulphasalazine) or monotherapy for three years. Rheumatology 41:892–898 PubMedCrossRef
191.
Zurück zum Zitat Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R (1998) A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 37:1060–1068 PubMedCrossRef Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R (1998) A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 37:1060–1068 PubMedCrossRef
192.
Zurück zum Zitat Rau R, Herborn G, Menninger H, Sangha O (2002) Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology 41:196–204 PubMedCrossRef Rau R, Herborn G, Menninger H, Sangha O (2002) Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology 41:196–204 PubMedCrossRef
193.
Zurück zum Zitat Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (cobra slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1‑year results of carera, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511–520 PubMedCrossRef Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (cobra slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1‑year results of carera, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511–520 PubMedCrossRef
194.
Zurück zum Zitat Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39:655–665 PubMedCrossRef Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39:655–665 PubMedCrossRef
195.
Zurück zum Zitat Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726–733 PubMedCrossRef Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726–733 PubMedCrossRef
196.
Zurück zum Zitat Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European leflunomide study group. Lancet 353:259–266 PubMedCrossRef Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European leflunomide study group. Lancet 353:259–266 PubMedCrossRef
197.
Zurück zum Zitat Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide rheumatoid arthritis investigators group. Arch Intern Med 159:2542–2550 PubMedCrossRef Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide rheumatoid arthritis investigators group. Arch Intern Med 159:2542–2550 PubMedCrossRef
198.
Zurück zum Zitat Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443–1450 PubMedCrossRef Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443–1450 PubMedCrossRef
199.
Zurück zum Zitat Kimel M, Cifaldi M, Chen N, Revicki D (2008) Adalimumab plus methotrexate improved sf-36 scores and reduced the effect of rheumatoid arthritis (ra) on work activity for patients with early ra. J Rheumatol 35:206–215 PubMed Kimel M, Cifaldi M, Chen N, Revicki D (2008) Adalimumab plus methotrexate improved sf-36 scores and reduced the effect of rheumatoid arthritis (ra) on work activity for patients with early ra. J Rheumatol 35:206–215 PubMed
200.
Zurück zum Zitat Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL et al (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124–134 PubMedCrossRef Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL et al (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124–134 PubMedCrossRef
201.
Zurück zum Zitat Sarzi-Puttini P, D’Ingianna E, Fumagalli M, Scarpellini M, Fiorini T, Cherie-Ligniere EL et al (2005) An open, randomized comparison study of cyclosporine a, cyclosporine a + methotrexate and cyclosporine a + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int 25:15–22 PubMedCrossRef Sarzi-Puttini P, D’Ingianna E, Fumagalli M, Scarpellini M, Fiorini T, Cherie-Ligniere EL et al (2005) An open, randomized comparison study of cyclosporine a, cyclosporine a + methotrexate and cyclosporine a + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int 25:15–22 PubMedCrossRef
202.
Zurück zum Zitat Gerards AH, Landewé RBM, Prins APA, Bruyn GW, Goei Thé HS, Laan RFJM et al (2003) Cyclosporin a monotherapy versus cyclosporin a and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 62:291–296 PubMedPubMedCentralCrossRef Gerards AH, Landewé RBM, Prins APA, Bruyn GW, Goei Thé HS, Laan RFJM et al (2003) Cyclosporin a monotherapy versus cyclosporin a and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 62:291–296 PubMedPubMedCentralCrossRef
203.
Zurück zum Zitat Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S (2003) Radiographic progression in early rheumatoid arthritis: A 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 42:1545–1549 PubMedCrossRef Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S (2003) Radiographic progression in early rheumatoid arthritis: A 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 42:1545–1549 PubMedCrossRef
204.
Zurück zum Zitat Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R et al (2007) Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 56:3919–3927 PubMedCrossRef Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R et al (2007) Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 56:3919–3927 PubMedCrossRef
205.
Zurück zum Zitat Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E et al (2006) Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 54:716–722 PubMedCrossRef Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E et al (2006) Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 54:716–722 PubMedCrossRef
206.
Zurück zum Zitat Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A et al (2010) Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The comet trial. Ann Rheum Dis 69:222–225 PubMedCrossRef Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A et al (2010) Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The comet trial. Ann Rheum Dis 69:222–225 PubMedCrossRef
207.
Zurück zum Zitat Ma MH, Kingsley GH, Scott DL (2010) A systematic comparison of combination dmard therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology 49:91–98 PubMedCrossRef Ma MH, Kingsley GH, Scott DL (2010) A systematic comparison of combination dmard therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology 49:91–98 PubMedCrossRef
208.
Zurück zum Zitat Katchamart W, Trudeau J, Phumethum V, Bombardier C (2009) Efficacy and toxicity of methotrexate (mtx) monotherapy versus mtx combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: A systematic review and meta-analysis. Ann Rheum Dis 68:1105–1112 PubMedCrossRef Katchamart W, Trudeau J, Phumethum V, Bombardier C (2009) Efficacy and toxicity of methotrexate (mtx) monotherapy versus mtx combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: A systematic review and meta-analysis. Ann Rheum Dis 68:1105–1112 PubMedCrossRef
210.
Zurück zum Zitat Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD et al (2008) Triple therapy in early active rheumatoid arthritis: A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 58:1310–1317 PubMedCrossRef Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD et al (2008) Triple therapy in early active rheumatoid arthritis: A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 58:1310–1317 PubMedCrossRef
211.
Zurück zum Zitat Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA et al (2007) Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled mascot study. Ann Rheum Dis 66:235–241 PubMedCrossRef Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA et al (2007) Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled mascot study. Ann Rheum Dis 66:235–241 PubMedCrossRef
212.
Zurück zum Zitat Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L et al (2008) Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67:656–663 PubMedCrossRef Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L et al (2008) Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67:656–663 PubMedCrossRef
213.
Zurück zum Zitat Le Loet X, Berthelot JM, Cantagrel A, Combe B, De Bandt M, Fautrel B et al (2006) Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: A 2004 proposal of the french society of rheumatology. Ann Rheum Dis 65:45–50 PubMedCrossRef Le Loet X, Berthelot JM, Cantagrel A, Combe B, De Bandt M, Fautrel B et al (2006) Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: A 2004 proposal of the french society of rheumatology. Ann Rheum Dis 65:45–50 PubMedCrossRef
215.
Zurück zum Zitat Hider SL, Silman A, Bunn D, Manning S, Symmons D, Lunt M (2006) Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis. Ann Rheum Dis 65:1449–1455 PubMedPubMedCentralCrossRef Hider SL, Silman A, Bunn D, Manning S, Symmons D, Lunt M (2006) Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis. Ann Rheum Dis 65:1449–1455 PubMedPubMedCentralCrossRef
216.
Zurück zum Zitat Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M et al (2018) S2e-leitlinie: Therapie der rheumatoiden arthritis mit krankheitsmodifizierenden medikamenten. Z Rheumatol 77:35–53 PubMedCrossRef Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M et al (2018) S2e-leitlinie: Therapie der rheumatoiden arthritis mit krankheitsmodifizierenden medikamenten. Z Rheumatol 77:35–53 PubMedCrossRef
217.
Zurück zum Zitat Felson DT, Anderson JJ, Meenan RF (1992) Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 35:1117–1125 PubMedCrossRef Felson DT, Anderson JJ, Meenan RF (1992) Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 35:1117–1125 PubMedCrossRef
218.
Zurück zum Zitat van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ et al (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515–1524 PubMedCrossRef van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ et al (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515–1524 PubMedCrossRef
220.
Zurück zum Zitat Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA (2017) Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin 15(3):133–139 PubMedCrossRef Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA (2017) Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin 15(3):133–139 PubMedCrossRef
221.
Zurück zum Zitat Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-tnf antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285 PubMedCrossRef Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-tnf antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285 PubMedCrossRef
222.
Zurück zum Zitat Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D et al (2017) Safety of synthetic and biological dmards: A systematic literature review informing the 2016 update of the eular recommendations for management of rheumatoid arthritis. Ann Rheum Dis 76:1101–1136 PubMedCrossRef Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D et al (2017) Safety of synthetic and biological dmards: A systematic literature review informing the 2016 update of the eular recommendations for management of rheumatoid arthritis. Ann Rheum Dis 76:1101–1136 PubMedCrossRef
223.
Zurück zum Zitat Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W et al (2017) Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic dmards. Ann Rheum Dis 76:504–510 PubMedCrossRef Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W et al (2017) Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic dmards. Ann Rheum Dis 76:504–510 PubMedCrossRef
224.
Zurück zum Zitat Krüger K, Albrecht K, Rehart S, Scholz R, der Kommission Pharmakotherapie D (2014) Recommendations of the german society for rheumatology on the perioperative approach under therapy with dmards and biologicals in inflammatory rheumatic diseases. Z Rheumatol 73:77–84 PubMedCrossRef Krüger K, Albrecht K, Rehart S, Scholz R, der Kommission Pharmakotherapie D (2014) Recommendations of the german society for rheumatology on the perioperative approach under therapy with dmards and biologicals in inflammatory rheumatic diseases. Z Rheumatol 73:77–84 PubMedCrossRef
225.
Zurück zum Zitat Asten P, Barrett J, Symmons D (1999) Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26:1705–1714 PubMed Asten P, Barrett J, Symmons D (1999) Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26:1705–1714 PubMed
226.
Zurück zum Zitat Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study. BMJ 317:180–181 PubMedPubMedCentralCrossRef Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study. BMJ 317:180–181 PubMedPubMedCentralCrossRef
227.
Zurück zum Zitat Beauparlant P, Papp K, Haraoui B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:148–158 PubMedCrossRef Beauparlant P, Papp K, Haraoui B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:148–158 PubMedCrossRef
228.
Zurück zum Zitat Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701 PubMedCrossRef Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701 PubMedCrossRef
229.
Zurück zum Zitat Maneiro JR, Souto A, Gomez-Reino JJ (2017) Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum 47:149–156 PubMedCrossRef Maneiro JR, Souto A, Gomez-Reino JJ (2017) Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum 47:149–156 PubMedCrossRef
230.
Zurück zum Zitat Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 60:3180–3189 PubMedCrossRef Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 60:3180–3189 PubMedCrossRef
231.
Zurück zum Zitat Wadström H, Frisell T, Askling J, The Anti-Rheumatic Therapy in Sweden Study G (2017) Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from sweden. JAMA Intern Med 177:1605 PubMedPubMedCentralCrossRef Wadström H, Frisell T, Askling J, The Anti-Rheumatic Therapy in Sweden Study G (2017) Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from sweden. JAMA Intern Med 177:1605 PubMedPubMedCentralCrossRef
232.
Zurück zum Zitat Laan RF, Jansen TL, van Riel PL (1999) Glucocorticosteroids in the management of rheumatoid arthritis. Rheumatology 38:6–12 PubMedCrossRef Laan RF, Jansen TL, van Riel PL (1999) Glucocorticosteroids in the management of rheumatoid arthritis. Rheumatology 38:6–12 PubMedCrossRef
233.
Zurück zum Zitat Gotzsche PC, Johansen HK (1998) Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 316:811–818 PubMedPubMedCentralCrossRef Gotzsche PC, Johansen HK (1998) Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 316:811–818 PubMedPubMedCentralCrossRef
235.
Zurück zum Zitat ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van Schaardenburg D et al (2015) Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1‑year results of the cobra-light open-label, randomised, non-inferiority trial. Ann Rheum Dis 74:1233–1240 PubMed ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van Schaardenburg D et al (2015) Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1‑year results of the cobra-light open-label, randomised, non-inferiority trial. Ann Rheum Dis 74:1233–1240 PubMed
236.
Zurück zum Zitat Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E et al (2008) Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (capra-1): A double-blind, randomised controlled trial. Lancet 371:205–214 PubMedCrossRef Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E et al (2008) Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (capra-1): A double-blind, randomised controlled trial. Lancet 371:205–214 PubMedCrossRef
237.
Zurück zum Zitat Gestel AMV, Laan RFJM, Haagsma CJ, Van De Putte LBA, Van Riel PLCM (1995) Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Baillieres Clin Rheumatol 34:347–351 Gestel AMV, Laan RFJM, Haagsma CJ, Van De Putte LBA, Van Riel PLCM (1995) Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Baillieres Clin Rheumatol 34:347–351
238.
Zurück zum Zitat Million R, Kellgren JH, Poole P, Jayson MI (1984) Long-term study of management of rheumatoid arthritis. Lancet 1:812–816 PubMedCrossRef Million R, Kellgren JH, Poole P, Jayson MI (1984) Long-term study of management of rheumatoid arthritis. Lancet 1:812–816 PubMedCrossRef
239.
Zurück zum Zitat Kirwan JR, Reeback JS (1986) Stanford health assessment questionnaire modified to assess disability in british patients with rheumatoid arthritis. Br J Rheumatol 25:206–209 PubMedCrossRef Kirwan JR, Reeback JS (1986) Stanford health assessment questionnaire modified to assess disability in british patients with rheumatoid arthritis. Br J Rheumatol 25:206–209 PubMedCrossRef
240.
Zurück zum Zitat Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group. N Engl J Med 333:142–146 PubMedCrossRef Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group. N Engl J Med 333:142–146 PubMedCrossRef
241.
Zurück zum Zitat Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977 PubMedCrossRef Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977 PubMedCrossRef
242.
Zurück zum Zitat Hickling P, Jacoby RK, Kirwan JR (1998) Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and rheumatism council low dose glucocorticoid study group. Br J Rheumatol 37:930–936 PubMedCrossRef Hickling P, Jacoby RK, Kirwan JR (1998) Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and rheumatism council low dose glucocorticoid study group. Br J Rheumatol 37:930–936 PubMedCrossRef
244.
Zurück zum Zitat van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1–12 PubMedCrossRef van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1–12 PubMedCrossRef
245.
Zurück zum Zitat Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156:329–339 PubMedCrossRef Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156:329–339 PubMedCrossRef
246.
Zurück zum Zitat McDougall R, Sibley J, Haga M, Russell A (1994) Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 21:1207–1213 PubMed McDougall R, Sibley J, Haga M, Russell A (1994) Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 21:1207–1213 PubMed
247.
Zurück zum Zitat Saag KG (1997) Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence. Am J Med 103:31S–39S PubMedCrossRef Saag KG (1997) Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence. Am J Med 103:31S–39S PubMedCrossRef
248.
Zurück zum Zitat Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115–123 PubMedCrossRef Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115–123 PubMedCrossRef
249.
Zurück zum Zitat Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494 PubMedCrossRef Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494 PubMedCrossRef
250.
Zurück zum Zitat Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: Viewpoints from an eular task force. Ann Rheum Dis 75:952–957 PubMedCrossRef Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: Viewpoints from an eular task force. Ann Rheum Dis 75:952–957 PubMedCrossRef
251.
Zurück zum Zitat Seror P, Pluvinage P, d’Andre FL, Benamou P, Attuil G (1999) Frequency of sepsis after local corticosteroid injection (an inquiry on 1160000 injections in rheumatological private practice in france). Rheumatology 38:1272–1274 PubMedCrossRef Seror P, Pluvinage P, d’Andre FL, Benamou P, Attuil G (1999) Frequency of sepsis after local corticosteroid injection (an inquiry on 1160000 injections in rheumatological private practice in france). Rheumatology 38:1272–1274 PubMedCrossRef
252.
Zurück zum Zitat Weitoft T, Uddenfeldt P (2000) Importance of synovial fluid aspiration when injecting intra-articular corticosteroids. Ann Rheum Dis 59:233–235 PubMedPubMedCentralCrossRef Weitoft T, Uddenfeldt P (2000) Importance of synovial fluid aspiration when injecting intra-articular corticosteroids. Ann Rheum Dis 59:233–235 PubMedPubMedCentralCrossRef
253.
Zurück zum Zitat Chakravarty K, Pharoah PD, Scott DG (1994) A randomized controlled study of post-injection rest following intra-articular steroid therapy for knee synovitis. Br J Rheumatol 33:464–468 PubMedCrossRef Chakravarty K, Pharoah PD, Scott DG (1994) A randomized controlled study of post-injection rest following intra-articular steroid therapy for knee synovitis. Br J Rheumatol 33:464–468 PubMedCrossRef
255.
Zurück zum Zitat Brooks PM, Day RO (1991) Nonsteroidal antiinflammatory drugs—differences and similarities. N Engl J Med 324:1716–1725 PubMedCrossRef Brooks PM, Day RO (1991) Nonsteroidal antiinflammatory drugs—differences and similarities. N Engl J Med 324:1716–1725 PubMedCrossRef
256.
Zurück zum Zitat Furst DE (1994) Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 37:1–9 PubMedCrossRef Furst DE (1994) Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 37:1–9 PubMedCrossRef
257.
Zurück zum Zitat van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA (2015) Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase‑2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: A network meta-analysis. Arthritis Res Ther 17:66 PubMedPubMedCentralCrossRef van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA (2015) Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase‑2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: A network meta-analysis. Arthritis Res Ther 17:66 PubMedPubMedCentralCrossRef
259.
Zurück zum Zitat Nsaids GPC (2010) BMJ clinical evidence 2010 Nsaids GPC (2010) BMJ clinical evidence 2010
260.
Zurück zum Zitat Hardin JG Jr., Kirk KA (1979) Comparative effectiveness of five analgesics for the pain of rheumatoid synovitis. J Rheumatol 6:405–412 PubMed Hardin JG Jr., Kirk KA (1979) Comparative effectiveness of five analgesics for the pain of rheumatoid synovitis. J Rheumatol 6:405–412 PubMed
262.
Zurück zum Zitat Seideman P, Melander A (1988) Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. Br J Rheumatol 27:117–122 PubMedCrossRef Seideman P, Melander A (1988) Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. Br J Rheumatol 27:117–122 PubMedCrossRef
264.
Zurück zum Zitat Moore RA, Derry S, Wiffen PJ, Straube S, Aldington DJ (2015) Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. Eur J Pain 19:1213–1223 PubMedCrossRef Moore RA, Derry S, Wiffen PJ, Straube S, Aldington DJ (2015) Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. Eur J Pain 19:1213–1223 PubMedCrossRef
267.
Zurück zum Zitat Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006) Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174:1589–1594 PubMedPubMedCentralCrossRef Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006) Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174:1589–1594 PubMedPubMedCentralCrossRef
268.
Zurück zum Zitat Bell MJ, Lineker SC, Wilkins AL, Goldsmith CH, Badley EM (1998) A randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis. J Rheumatol 25:231–237 PubMed Bell MJ, Lineker SC, Wilkins AL, Goldsmith CH, Badley EM (1998) A randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis. J Rheumatol 25:231–237 PubMed
269.
Zurück zum Zitat Mayoux Benhamou MA (2007) Reconditioning in patients with rheumatoid arthritis. Ann Readapt Med Phys 50:382–5, 77–81 PubMedCrossRef Mayoux Benhamou MA (2007) Reconditioning in patients with rheumatoid arthritis. Ann Readapt Med Phys 50:382–5, 77–81 PubMedCrossRef
270.
Zurück zum Zitat Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, Treharne GJ, Panoulas VF, Douglas KM et al (2008) Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology 47:239–248 PubMedCrossRef Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, Treharne GJ, Panoulas VF, Douglas KM et al (2008) Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology 47:239–248 PubMedCrossRef
271.
Zurück zum Zitat Neill J, Belan I, Ried K (2006) Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: A systematic review. J Adv Nurs 56:617–635 PubMedCrossRef Neill J, Belan I, Ried K (2006) Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: A systematic review. J Adv Nurs 56:617–635 PubMedCrossRef
272.
Zurück zum Zitat Wessel J (2004) The effectiveness of hand exercises for persons with rheumatoid arthritis: a systematic review. J Hand Ther 17:174–180 PubMedCrossRef Wessel J (2004) The effectiveness of hand exercises for persons with rheumatoid arthritis: a systematic review. J Hand Ther 17:174–180 PubMedCrossRef
273.
Zurück zum Zitat Eversden L, Maggs F, Nightingale P, Jobanputra P (2007) A pragmatic randomised controlled trial of hydrotherapy and land exercises on overall well being and quality of life in rheumatoid arthritis. BMC Musculoskelet Disord 8:23 PubMedPubMedCentralCrossRef Eversden L, Maggs F, Nightingale P, Jobanputra P (2007) A pragmatic randomised controlled trial of hydrotherapy and land exercises on overall well being and quality of life in rheumatoid arthritis. BMC Musculoskelet Disord 8:23 PubMedPubMedCentralCrossRef
275.
Zurück zum Zitat Baillet A, Zeboulon N, Gossec L, Combescure C, Bodin LA, Juvin R et al (2010) Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. Arthritis Care Res 62:984–992 CrossRef Baillet A, Zeboulon N, Gossec L, Combescure C, Bodin LA, Juvin R et al (2010) Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. Arthritis Care Res 62:984–992 CrossRef
276.
Zurück zum Zitat Bulthuis Y, Drossaers-Bakker KW, Taal E, Rasker J, Oostveen J, van’t Pad Bosch P et al (2007) Arthritis patients show long-term benefits from 3 weeks intensive exercise training directly following hospital discharge. Baillieres Clin Rheumatol 46:1712–1717 Bulthuis Y, Drossaers-Bakker KW, Taal E, Rasker J, Oostveen J, van’t Pad Bosch P et al (2007) Arthritis patients show long-term benefits from 3 weeks intensive exercise training directly following hospital discharge. Baillieres Clin Rheumatol 46:1712–1717
277.
Zurück zum Zitat Bulthuis Y, Mohammad S, Braakman-Jansen LM, Drossaers-Bakker KW, van de Laar MA (2008) Cost-effectiveness of intensive exercise therapy directly following hospital discharge in patients with arthritis: Results of a randomized controlled clinical trial. Arthritis Rheum 59:247–254 PubMedCrossRef Bulthuis Y, Mohammad S, Braakman-Jansen LM, Drossaers-Bakker KW, van de Laar MA (2008) Cost-effectiveness of intensive exercise therapy directly following hospital discharge in patients with arthritis: Results of a randomized controlled clinical trial. Arthritis Rheum 59:247–254 PubMedCrossRef
278.
Zurück zum Zitat Gaudin P, Leguen-Guegan S, Allenet B, Baillet A, Grange L, Juvin R (2008) Is dynamic exercise beneficial in patients with rheumatoid arthritis? Joint Bone Spine 75:11–17 PubMedCrossRef Gaudin P, Leguen-Guegan S, Allenet B, Baillet A, Grange L, Juvin R (2008) Is dynamic exercise beneficial in patients with rheumatoid arthritis? Joint Bone Spine 75:11–17 PubMedCrossRef
279.
Zurück zum Zitat Neuberger GB, Aaronson LS, Gajewski B, Embretson SE, Cagle PE, Loudon JK et al (2007) Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness, and disease outcomes of rheumatoid arthritis. Arthritis Rheum 57:943–952 PubMedCrossRef Neuberger GB, Aaronson LS, Gajewski B, Embretson SE, Cagle PE, Loudon JK et al (2007) Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness, and disease outcomes of rheumatoid arthritis. Arthritis Rheum 57:943–952 PubMedCrossRef
280.
Zurück zum Zitat Plasqui G (2008) The role of physical activity in rheumatoid arthritis. Physiol Behav 94:270–275 PubMedCrossRef Plasqui G (2008) The role of physical activity in rheumatoid arthritis. Physiol Behav 94:270–275 PubMedCrossRef
281.
Zurück zum Zitat Cairns AP, McVeigh JG (2009) A systematic review of the effects of dynamic exercise in rheumatoid arthritis. Rheumatol Int 30:147–158 PubMedCrossRef Cairns AP, McVeigh JG (2009) A systematic review of the effects of dynamic exercise in rheumatoid arthritis. Rheumatol Int 30:147–158 PubMedCrossRef
282.
Zurück zum Zitat Hsieh LF, Chen SC, Chuang CC, Chai HM, Chen WS, He YC (2009) Supervised aerobic exercise is more effective than home aerobic exercise in female chinese patients with rheumatoid arthritis. J Rehabil Med 41:332–337 PubMedCrossRef Hsieh LF, Chen SC, Chuang CC, Chai HM, Chen WS, He YC (2009) Supervised aerobic exercise is more effective than home aerobic exercise in female chinese patients with rheumatoid arthritis. J Rehabil Med 41:332–337 PubMedCrossRef
284.
Zurück zum Zitat Balsamo S, Diniz LR, dos Santos-Neto LL, da Mota LM (2014) Exercise and fatigue in rheumatoid arthritis. Isr Med Assoc J 16:57–60 PubMed Balsamo S, Diniz LR, dos Santos-Neto LL, da Mota LM (2014) Exercise and fatigue in rheumatoid arthritis. Isr Med Assoc J 16:57–60 PubMed
285.
Zurück zum Zitat Cramp F, Berry J, Gardiner M, Smith F, Stephens D (2013) Health behaviour change interventions for the promotion of physical activity in rheumatoid arthritis: A systematic review. Musculoskelet Care 11:238–247 CrossRef Cramp F, Berry J, Gardiner M, Smith F, Stephens D (2013) Health behaviour change interventions for the promotion of physical activity in rheumatoid arthritis: A systematic review. Musculoskelet Care 11:238–247 CrossRef
288.
Zurück zum Zitat de Jong Z, Munneke M, Zwinderman AH, Kroon HM, Jansen A, Ronday KH et al (2003) Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 48:2415–2424 PubMedCrossRef de Jong Z, Munneke M, Zwinderman AH, Kroon HM, Jansen A, Ronday KH et al (2003) Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 48:2415–2424 PubMedCrossRef
289.
Zurück zum Zitat van den Berg MH, Ronday HK, Peeters AJ, le Cessie S, van der Giesen FJ, Breedveld FC et al (2006) Using internet technology to deliver a home-based physical activity intervention for patients with rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 55:935–945 PubMedCrossRef van den Berg MH, Ronday HK, Peeters AJ, le Cessie S, van der Giesen FJ, Breedveld FC et al (2006) Using internet technology to deliver a home-based physical activity intervention for patients with rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 55:935–945 PubMedCrossRef
291.
Zurück zum Zitat Verhagen AP, Bierma-Zeinstra SM, Boers M, Cardoso JR, Lambeck J, De Bie R et al (2015) Balneotherapy (or spa therapy) for rheumatoid arthritis. An abridged version of cochrane systematic review. Eur J Phys Rehabil Med 51:833–847 PubMed Verhagen AP, Bierma-Zeinstra SM, Boers M, Cardoso JR, Lambeck J, De Bie R et al (2015) Balneotherapy (or spa therapy) for rheumatoid arthritis. An abridged version of cochrane systematic review. Eur J Phys Rehabil Med 51:833–847 PubMed
294.
Zurück zum Zitat Hirvonen HE, Mikkelsson MK, Kautiainen H, Pohjolainen TH, Leirisalo-Repo M (2006) Effectiveness of different cryotherapies on pain and disease activity in active rheumatoid arthritis. A randomised single blinded controlled trial. Clin Exp Rheumatol 24:295–301 PubMed Hirvonen HE, Mikkelsson MK, Kautiainen H, Pohjolainen TH, Leirisalo-Repo M (2006) Effectiveness of different cryotherapies on pain and disease activity in active rheumatoid arthritis. A randomised single blinded controlled trial. Clin Exp Rheumatol 24:295–301 PubMed
297.
Zurück zum Zitat Meireles SM, Jones A, Jennings F, Suda AL, Parizotto NA, Natour J (2010) Assessment of the effectiveness of low-level laser therapy on the hands of patients with rheumatoid arthritis: A randomized double-blind controlled trial. Clin Rheumatol 29:501–509 PubMedCrossRef Meireles SM, Jones A, Jennings F, Suda AL, Parizotto NA, Natour J (2010) Assessment of the effectiveness of low-level laser therapy on the hands of patients with rheumatoid arthritis: A randomized double-blind controlled trial. Clin Rheumatol 29:501–509 PubMedCrossRef
300.
Zurück zum Zitat Evans S, Moieni M, Lung K, Tsao J, Sternlieb B, Taylor M et al (2013) Impact of iyengar yoga on quality of life in young women with rheumatoid arthritis. Clin J Pain 29:988–997 PubMedPubMedCentralCrossRef Evans S, Moieni M, Lung K, Tsao J, Sternlieb B, Taylor M et al (2013) Impact of iyengar yoga on quality of life in young women with rheumatoid arthritis. Clin J Pain 29:988–997 PubMedPubMedCentralCrossRef
304.
Zurück zum Zitat Lee MS, Pittler MH, Ernst E (2007) Tai chi for rheumatoid arthritis: Systematic review. Rheumatology 46:1648–1651 PubMedCrossRef Lee MS, Pittler MH, Ernst E (2007) Tai chi for rheumatoid arthritis: Systematic review. Rheumatology 46:1648–1651 PubMedCrossRef
305.
Zurück zum Zitat Steultjens EM, Dekker J, Bouter LM, Leemrijse CJ, van den Ende CH (2005) Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews. Clin Rehabil 19:247–254 PubMedCrossRef Steultjens EM, Dekker J, Bouter LM, Leemrijse CJ, van den Ende CH (2005) Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews. Clin Rehabil 19:247–254 PubMedCrossRef
306.
Zurück zum Zitat Steultjens EM, Dekker J, Bouter LM, van Schaardenburg D, van Kuyk MA, van den Ende CH (2002) Occupational therapy for rheumatoid arthritis: a systematic review. Arthritis Rheum 47:672–685 PubMedCrossRef Steultjens EM, Dekker J, Bouter LM, van Schaardenburg D, van Kuyk MA, van den Ende CH (2002) Occupational therapy for rheumatoid arthritis: a systematic review. Arthritis Rheum 47:672–685 PubMedCrossRef
307.
Zurück zum Zitat Lamb SE, Williamson EM, Heine PJ, Adams J, Dosanjh S, Dritsaki M et al (2015) Exercises to improve function of the rheumatoid hand (sarah): A randomised controlled trial. Lancet 385:421–429 PubMedCrossRef Lamb SE, Williamson EM, Heine PJ, Adams J, Dosanjh S, Dritsaki M et al (2015) Exercises to improve function of the rheumatoid hand (sarah): A randomised controlled trial. Lancet 385:421–429 PubMedCrossRef
311.
Zurück zum Zitat Baldwin D, Johnstone B, Ge B, Hewett J, Smith M, Sharp G (2012) Randomized prospective study of a work place ergonomic intervention for individuals with rheumatoid arthritis and osteoarthritis. Arthritis Care Res 64:1527–1535 CrossRef Baldwin D, Johnstone B, Ge B, Hewett J, Smith M, Sharp G (2012) Randomized prospective study of a work place ergonomic intervention for individuals with rheumatoid arthritis and osteoarthritis. Arthritis Care Res 64:1527–1535 CrossRef
313.
Zurück zum Zitat Conceicao CS, Gomes Neto M, Mendes SM, Sa KN, Baptista AF (2015) Systematic review and meta-analysis of effects of foot orthoses on pain and disability in rheumatoid arthritis patients. Disabil Rehabil 37:1209–1213 CrossRefPubMed Conceicao CS, Gomes Neto M, Mendes SM, Sa KN, Baptista AF (2015) Systematic review and meta-analysis of effects of foot orthoses on pain and disability in rheumatoid arthritis patients. Disabil Rehabil 37:1209–1213 CrossRefPubMed
315.
Zurück zum Zitat Hennessy K, Woodburn J, Steultjens MP (2012) Custom foot orthoses for rheumatoid arthritis: a systematic review. Arthritis Care Res 64:311–320 CrossRef Hennessy K, Woodburn J, Steultjens MP (2012) Custom foot orthoses for rheumatoid arthritis: a systematic review. Arthritis Care Res 64:311–320 CrossRef
319.
Zurück zum Zitat Astin JA, Beckner W, Soeken K, Hochberg MC, Berman B (2002) Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 47:291–302 PubMedCrossRef Astin JA, Beckner W, Soeken K, Hochberg MC, Berman B (2002) Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 47:291–302 PubMedCrossRef
320.
Zurück zum Zitat Dixon KE, Keefe FJ, Scipio CD, Perri LM, Abernethy AP (2007) Psychological interventions for arthritis pain management in adults: A meta-analysis. Health Psychol 26:241–250 PubMedCrossRef Dixon KE, Keefe FJ, Scipio CD, Perri LM, Abernethy AP (2007) Psychological interventions for arthritis pain management in adults: A meta-analysis. Health Psychol 26:241–250 PubMedCrossRef
321.
Zurück zum Zitat Evers AW, Kraaimaat FW, van Riel PL, de Jong AJ (2002) Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: A randomized controlled trial. Pain 100:141–153 PubMedCrossRef Evers AW, Kraaimaat FW, van Riel PL, de Jong AJ (2002) Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: A randomized controlled trial. Pain 100:141–153 PubMedCrossRef
322.
Zurück zum Zitat Savelkoul M, de Witte L, Post M (2003) Stimulating active coping in patients with rheumatic diseases: a systematic review of controlled group intervention studies. Patient Educ Couns 50:133–143 PubMedCrossRef Savelkoul M, de Witte L, Post M (2003) Stimulating active coping in patients with rheumatic diseases: a systematic review of controlled group intervention studies. Patient Educ Couns 50:133–143 PubMedCrossRef
323.
Zurück zum Zitat Sharpe L, Allard S, Sensky T (2008) Five-year followup of a cognitive-behavioral intervention for patients with recently-diagnosed rheumatoid arthritis: effects on health care utilization. Arthritis Rheum 59:311–316 PubMedCrossRef Sharpe L, Allard S, Sensky T (2008) Five-year followup of a cognitive-behavioral intervention for patients with recently-diagnosed rheumatoid arthritis: effects on health care utilization. Arthritis Rheum 59:311–316 PubMedCrossRef
324.
Zurück zum Zitat Sharpe L, Sensky T, Timberlake N, Ryan B, Allard S (2003) Long-term efficacy of a cognitive behavioural treatment from a randomized controlled trial for patients recently diagnosed with rheumatoid arthritis. Rheumatology 42:435–441 PubMedCrossRef Sharpe L, Sensky T, Timberlake N, Ryan B, Allard S (2003) Long-term efficacy of a cognitive behavioural treatment from a randomized controlled trial for patients recently diagnosed with rheumatoid arthritis. Rheumatology 42:435–441 PubMedCrossRef
330.
Zurück zum Zitat Lee MS, Shin BC, Ernst E (2008) Acupuncture for rheumatoid arthritis: a systematic review. Rheumatology 47:1747–1753 PubMedCrossRef Lee MS, Shin BC, Ernst E (2008) Acupuncture for rheumatoid arthritis: a systematic review. Rheumatology 47:1747–1753 PubMedCrossRef
331.
Zurück zum Zitat Wang C, de Pablo P, Chen X, Schmid C, McAlindon T (2008) Acupuncture for pain relief in patients with rheumatoid arthritis: A systematic review. Arthritis Rheum 59:1249–1256 PubMedCrossRef Wang C, de Pablo P, Chen X, Schmid C, McAlindon T (2008) Acupuncture for pain relief in patients with rheumatoid arthritis: A systematic review. Arthritis Rheum 59:1249–1256 PubMedCrossRef
332.
Zurück zum Zitat Park J, Ernst E (2005) Ayurvedic medicine for rheumatoid arthritis: A systematic review. Semin Arthritis Rheum 34:705–713 PubMedCrossRef Park J, Ernst E (2005) Ayurvedic medicine for rheumatoid arthritis: A systematic review. Semin Arthritis Rheum 34:705–713 PubMedCrossRef
334.
Zurück zum Zitat Macfarlane GJ, El-Metwally A, De Silva V, Ernst E, Dowds GL, Moots RJ (2011) Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: A systematic review. Rheumatology 50:1672–1683 PubMedCrossRef Macfarlane GJ, El-Metwally A, De Silva V, Ernst E, Dowds GL, Moots RJ (2011) Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: A systematic review. Rheumatology 50:1672–1683 PubMedCrossRef
335.
Zurück zum Zitat Wang HL, Jiang Q, Feng XH, Zhang HD, Ge L, Luo CG et al (2016) Tripterygium wilfordii hook f versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: A systematic review and network meta-analysis. BMC Complement Altern Med 16:215 PubMedPubMedCentralCrossRef Wang HL, Jiang Q, Feng XH, Zhang HD, Ge L, Luo CG et al (2016) Tripterygium wilfordii hook f versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: A systematic review and network meta-analysis. BMC Complement Altern Med 16:215 PubMedPubMedCentralCrossRef
336.
Zurück zum Zitat Wang X, Zu Y, Huang L, Yu J, Zhao H, Wen C et al (2017) Treatment of rheumatoid arthritis with combination of methotrexate and tripterygium wilfordii: a meta-analysis. Life Sci 171:45–50 PubMedCrossRef Wang X, Zu Y, Huang L, Yu J, Zhao H, Wen C et al (2017) Treatment of rheumatoid arthritis with combination of methotrexate and tripterygium wilfordii: a meta-analysis. Life Sci 171:45–50 PubMedCrossRef
337.
Zurück zum Zitat Zhang W, Shi Q, Zhao LD, Li Y, Tang FL, Zhang FC et al (2010) The safety and effectiveness of a chloroform/methanol extract of tripterygium wilfordii hook f (t2) plus methotrexate in treating rheumatoid arthritis. J Clin Rheumatol 16:375–378 PubMedCrossRef Zhang W, Shi Q, Zhao LD, Li Y, Tang FL, Zhang FC et al (2010) The safety and effectiveness of a chloroform/methanol extract of tripterygium wilfordii hook f (t2) plus methotrexate in treating rheumatoid arthritis. J Clin Rheumatol 16:375–378 PubMedCrossRef
340.
Zurück zum Zitat Jiang J, Li K, Wang F, Yang B, Fu Y, Zheng J et al (2016) Effect of marine-derived n‑3 polyunsaturated fatty acids on major eicosanoids: a systematic review and meta-analysis from 18 randomized controlled trials. PLoS ONE 11:e147351 PubMedPubMedCentralCrossRef Jiang J, Li K, Wang F, Yang B, Fu Y, Zheng J et al (2016) Effect of marine-derived n‑3 polyunsaturated fatty acids on major eicosanoids: a systematic review and meta-analysis from 18 randomized controlled trials. PLoS ONE 11:e147351 PubMedPubMedCentralCrossRef
344.
Zurück zum Zitat Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M et al (2015) Fish oil in recent onset rheumatoid arthritis: A randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis 74:89–95 PubMedCrossRef Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M et al (2015) Fish oil in recent onset rheumatoid arthritis: A randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis 74:89–95 PubMedCrossRef
345.
Zurück zum Zitat Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48 PubMedCrossRef Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48 PubMedCrossRef
346.
Zurück zum Zitat Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244–257 PubMedCrossRef Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244–257 PubMedCrossRef
347.
Zurück zum Zitat Aletaha D, Smolen J (2005) The simplified disease activity index (sdai) and the clinical disease activity index (cdai): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100–S108 PubMed Aletaha D, Smolen J (2005) The simplified disease activity index (sdai) and the clinical disease activity index (cdai): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100–S108 PubMed
Metadaten
Titel
Management der frühen rheumatoiden Arthritis
Interdisziplinäre Leitlinie
verfasst von
Prof. Dr. M. Schneider
G. Baseler
O. Funken
S. Heberger
U. Kiltz
P. Klose
K. Krüger
J. Langhorst
W. Mau
R. Oltman
B. Richter
S. Seitz
P. Sewerin
R. Tholen
C. Weseloh
Univ.-Prof. Dr. M. Witthöft
C. Specker
Publikationsdatum
01.06.2020

Neu im Fachgebiet Innere Medizin

Update Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.